About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Slc6a3
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3
MGI:94862
105 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Atg7tm1Tchi/Atg7tm1Tchi
Slc6a3tm1(cre)Xz/Slc6a3+
involves: 129S1/Sv * C57BL/6NCrlj * CBA/JNCrlj 		abnormal neuron morphology J:192452
abnormal substantia nigra pars compacta morphology J:192452
decreased dopamine level J:192452
hyperactivity J:192452
neuron degeneration J:192452
Chrna4tm1.1Tmcg/Chrna4tm1.1Tmcg
Slc6a3tm1(cre)Xz/Slc6a3+
involves: 129S/SvEv * 129S1/Sv * C57BL/6 		abnormal synaptic dopamine release J:174505
enhanced behavioral response to nicotine J:174505
impaired behavioral response to nicotine J:174505
impaired conditioned place preference behavior J:174505
Cox10tm1Ctm/Cox10tm1Ctm
Slc6a3tm1.1(cre)Bkmn/?
B6.Cg-Cox10tm1Ctm Slc6a3tm1.1(cre)Bkmn 		abnormal chemokine secretion J:231810
abnormal motor capabilities/coordination/movement J:231810
decreased body weight J:231810
decreased dopamine level J:231810
decreased dopaminergic neuron number J:231810
decreased locomotor activity J:231810
decreased vertical activity J:231810
impaired coordination J:231810
increased interleukin-1 beta secretion J:231810
increased microglial cell activation J:231810
loss of dopaminergic neurons J:231810
microgliosis J:231810
Drd2tm1.1Mrub/Drd2tm1.1Mrub
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
B6.Cg-Drd2tm1.1Mrub Slc6a3tm1.1(cre)Bkmn 		abnormal inhibitory postsynaptic currents J:176167
abnormal operant conditioning behavior J:176167
abnormal single cell response J:176167
abnormal synaptic dopamine release J:176167
decreased physiological sensitivity to xenobiotic J:176167
enhanced behavioral response to cocaine J:176167
hyperactivity J:176167
increased physiological sensitivity to xenobiotic J:176167
induced hyperactivity J:176167
Grin1tm1Rpa/Grin1tm1.1Rpa
Slc6a3tm1(cre)Xz/Slc6a3+
involves: 129S1/Sv 		abnormal behavioral response to addictive substance J:145468
abnormal excitatory postsynaptic currents J:145468
abnormal miniature excitatory postsynaptic currents J:145468
impaired conditioned place preference behavior J:145468
increased miniature excitatory postsynaptic current amplitude J:145468
increased miniature excitatory postsynaptic current frequency J:145468
reduced long-term potentiation J:145468
Gt(ROSA)26Sortm1.1(CAG-COX8A/Dendra2)Dcc/Gt(ROSA)26Sor+
Mfn1tm2Dcc/Mfn1tm2Dcc
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
involves: 129 * 129S6/SvEvTac * C57BL/6J * SJL/J 		no abnormal phenotype detected J:188347
Gt(ROSA)26Sortm1.1(CAG-COX8A/Dendra2)Dcc/Gt(ROSA)26Sor+
Mfn2tm3Dcc/Mfn2tm3Dcc
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
involves: 129 * 129S6/SvEvTac * C57BL/6J * SJL/J 		abnormal axonal transport J:188347
abnormal dopaminergic neuron morphology J:188347
abnormal innervation J:188347
abnormal mitochondrial morphology J:188347
abnormal striatum morphology J:188347
bradykinesia J:188347
decreased body size J:188347
decreased body weight J:188347
decreased locomotor activity J:188347
decreased vertical activity J:188347
hunched posture J:188347
kyphosis J:188347
loss of dopaminergic neurons J:188347
neurodegeneration J:188347
premature death J:188347
Gt(ROSA)26Sortm1.1(Otx2)Daac/Gt(ROSA)26Sor+
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 		decreased susceptibility to dopaminergic neuron neurotoxicity J:166896
Gt(ROSA)26Sortm1.1(Otx2)Daac/Gt(ROSA)26Sortm1.1(Otx2)Daac
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 		decreased dopaminergic neuron number J:166896
decreased susceptibility to dopaminergic neuron neurotoxicity J:166896
Gt(ROSA)26Sortm1.1(Otx2)Daac/Gt(ROSA)26Sortm1.1(Otx2)Daac
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
Tg(CAG-Otx2,-GFP)21Asim/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 		decreased dopaminergic neuron number J:166896
decreased susceptibility to dopaminergic neuron neurotoxicity J:166896
Gt(ROSA)26Sortm1Lrsn/Gt(ROSA)26Sor+
Prkntm1Roo/Prkntm1Roo
Slc6a3tm1(cre)Lrsn/Slc6a3+
Tfamtm1Lrsn/Tfamtm1Lrsn
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 		abnormal axonal transport J:176022
abnormal neuron morphology J:176022
loss of dopaminergic neurons J:176022
Gt(ROSA)26Sortm1Lrsn/Gt(ROSA)26Sor+
Slc6a3tm1(cre)Lrsn/Slc6a3+
Tfamtm1Lrsn/Tfamtm1Lrsn
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 		abnormal locomotor behavior J:176022
abnormal mitochondrial physiology J:176022
abnormal neuron morphology J:176022
loss of dopaminergic neurons J:176022
muscle hypertonia J:176022
weight loss J:176022
Gt(ROSA)26Sortm1Lrsn/Gt(ROSA)26Sor+
Mfn2tm1.1Arte/Mfn2tm1.1Arte
Slc6a3tm1(cre)Lrsn/Slc6a3+
involves: 129S1/Sv * 129X1/SvJ 		abnormal dopaminergic neuron morphology J:188337
abnormal dorsal striatum morphology J:188337
abnormal mitochondrial shape J:188337
decreased mitochondrial number J:188337
increased mitochondrial size J:188337
Kcnj6em1.1Ktaka/Kcnj6em1.1Ktaka
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
involves: C57BL/6J * C57BL/6N 		abnormal nervous system electrophysiology J:257982
behavioral despair J:257982
Lmx1atm1Tpe/Lmx1atm1Tpe
Lmx1btm1Zfc/Lmx1btm1Zfc
Slc6a3tm1(cre)Lrsn/Slc6a3+
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 		abnormal autophagy J:222854
abnormal innervation J:222854
abnormal lysosome morphology J:222854
abnormal lysosome physiology J:222854
abnormal synapse morphology J:222854
abnormal synaptic bouton morphology J:222854
abnormal synaptic vesicle number J:222854
decreased dopamine level J:222854
enhanced long-term potentiation J:222854
impaired coordination J:222854
impaired olfaction J:222854
impaired short-term object recognition memory J:222854
increased locomotor activity J:222854
neurodegeneration J:222854
Mapk14tm1.1Otsu/Mapk14tm1.2Otsu
Slc6a3tm1(cre)Xz/0
involves: 129S1/Sv * C57BL/6 		abnormal associative learning J:226396
normal behavior/neurological phenotype J:226396
Mfn1tm1.1Arte/Mfn1tm1.1Arte
Slc6a3tm1(cre)Lrsn/Slc6a3+
involves: 129S1/Sv * 129X1/SvJ 		no abnormal phenotype detected J:188337
Mfn2tm1.1Arte/Mfn2tm1.1Arte
Slc6a3tm1(cre)Lrsn/Slc6a3+
involves: 129S1/Sv * 129X1/SvJ 		abnormal innervation J:188337
abnormal locomotor activation J:188337
abnormal neuron physiology J:188337
abnormal respiratory electron transport chain J:188337
abnormal substantia nigra pars compacta morphology J:188337
decreased body weight J:188337
decreased dopamine level J:188337
decreased locomotor activity J:188337
decreased vertical activity J:188337
increased serotonin level J:188337
premature death J:188337
weight loss J:188337
Mlca4C57BL/6J/?
Slc6a3tm1Mca/Slc6a3+
involves: C57BL/6J * DBA/2J 		increased locomotor activity J:118059
Mlca5DBA/2J/?
Slc6a3tm1Mca/Slc6a3+
involves: C57BL/6J * DBA/2J 		increased locomotor activity J:118059
Nr4a2tm1.1Pcn/Nr4a2tm1.1Pcn
Slc6a3tm1(cre)Lrsn/Slc6a3tm1(cre)Lrsn
involves: 129S1/Sv * 129X1/SvJ 		abnormal dopaminergic neuron morphology J:157098
abnormal response/metabolism to endogenous compounds J:157098
decreased body size J:157098
decreased dopamine level J:157098
decreased locomotor activity J:157098
decreased vertical activity J:157098
hyperactivity J:157098
increased serotonin level J:157098
increased stereotypic behavior J:157098
lethality at weaning, complete penetrance J:157098
neuron degeneration J:157098
Oprk1tm2.1Kff/Oprk1tm2.1Kff
Slc6a3tm1(cre)Xz/0
involves: 129 * 129S1/Sv * C57BL/6 		abnormal associative learning J:226396
abnormal synaptic dopamine release J:226396
Otx2tm6Asim/Otx2tm11Asim
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ 		abnormal neuron differentiation J:166896
increased susceptibility to dopaminergic neuron neurotoxicity J:166896
Pink1tm1Zhzh/Pink1tm1Zhzh
Slc6a3tm4.1(tTA)Xz/?
Tg(tetO-SNCA*A53T)E2Cai/?
involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 		abnormal mitochondrial morphology J:218892
neuronal cytoplasmic inclusions J:218892
Prkntm1Shn/Prkntm1Shn
Slc6a3tm4.1(tTA)Xz/?
Tg(tetO-SNCA*A53T)E2Cai/?
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 		abnormal mitochondrial morphology J:218892
neuronal cytoplasmic inclusions J:218892
Ptentm1Hwu/Ptentm1Hwu
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
involves: 129S4/SvJae * C57BL/6 		abnormal behavioral response to xenobiotic J:153622
abnormal dopaminergic neuron morphology J:153622
abnormal midbrain morphology J:153622
abnormal nervous system physiology J:153622
abnormal striatum morphology J:153622
abnormal substantia nigra pars compacta morphology J:153622
abnormal substantia nigra pars reticulata morphology J:153622
normal behavior/neurological phenotype J:153622
increased dopamine level J:153622
neuron hypertrophy J:153622
Rettm1Kln/Rettm1Kln
Slc6a3tm1(cre)Xz/Slc6a3+
involves: 129S1/Sv 		abnormal synaptic dopamine release J:188348
loss of dopaminergic neurons J:188348
Rettm13.1Jmi/Rettm13Jmi
Slc6a3tm1(cre)Xz/Slc6a3+
involves: 129S1/Sv * 129X1/SvJ 		decreased locomotor activity J:114682
normal nervous system phenotype J:114682
Rpl22tm1.1Psam/Rpl22+
Slc6a3tm1(cre)Xz/Slc6a3+
involves: 129S1/Sv * 129X1/SvJ 		no abnormal phenotype detected J:151962
Shhtm1Ahk/Shhtm1Ahk
Slc6a3tm1(cre)Xz/Slc6a3+
involves: 129S1/Sv * C57BL/6 		abnormal gait J:188348
abnormal synaptic dopamine release J:188348
decreased dopamine level J:188348
decreased locomotor activity J:188348
decreased neuron number J:188348
hindlimb paralysis J:188348
hyperactivity J:188348
increased dopamine level J:188348
increased neuron number J:188348
loss of dopaminergic neurons J:188348
premature death J:188348
Slc6a3tm1(cre)Lrsn/Slc6a3+
Tfamtm1Lrsn/Tfamtm1Lrsn
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL 		abnormal dopaminergic neuron morphology J:119515
abnormal limb posture J:119515
decreased dopamine level J:119515
decreased exploration in new environment J:119515
decreased locomotor activity J:119515
loss of dopaminergic neurons J:119515
muscle spasm J:119515
neuronal intranuclear inclusions J:119515
premature death J:119515
tremors J:119515
Slc6a3tm1(cre)Lrsn/Slc6a3+
Sncatm1Nbm/Sncatm1Nbm
Tfamtm1Lrsn/Tfamtm1Lrsn
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * SJL 		neuronal intranuclear inclusions J:119515
Slc6a3tm1Mca/Slc6a3tm1Mca
Slc6a4tm1Kpl/Slc6a4+
involves: 129P2/OlaHsd * C57BL/6J 		impaired conditioned place preference behavior J:93114
Slc6a3tm1Mca/Slc6a3tm1Mca
Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129P2/OlaHsd * C57BL/6J 		abnormal adenohypophysis morphology J:93114
impaired conditioned place preference behavior J:93114
increased exploration in new environment J:93114
postnatal growth retardation J:93114
small pituitary gland J:93114
Slc6a3tm2(HBEGF)Rpa/Slc6a3+
involves: C57BL/6 		decreased dopamine level J:215916
loss of dopaminergic neurons J:215916
Slc6a3tm2(tTA)Xz/Slc6a3+
Tg(tetO-COX8A/PstI*)1Ctm/0
involves: 129X1/SvJ * C57BL/6 * C57BL/6J * SJL 		abnormal noradrenaline level J:178139
abnormal striatum morphology J:178139
abnormal substantia nigra morphology J:178139
abnormal synaptic bouton morphology J:178139
decreased dopamine level J:178139
decreased exploration in new environment J:178139
impaired coordination J:178139
increased serotonin level J:178139
slow postnatal weight gain J:178139
Slc6a3tm4.1(tTA)Xz/Slc6a3+
Tg(tetO-SNCA*A53T)E2Cai/0
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 		abnormal axon morphology J:218892
abnormal dendrite morphology J:218892
abnormal mitochondrial physiology J:218892
abnormal mitochondrial shape J:218892
decreased dopamine level J:218892
decreased mitochondrial size J:218892
loss of dopaminergic neurons J:218892
neuron degeneration J:218892
neuronal cytoplasmic inclusions J:218892
slow postnatal weight gain J:218892
Slc17a6tm1.1Thna/Slc17a6tm1.1Thna
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Slc6a3tm1(cre)Xz/Slc6a3+
involves: 129/Sv * 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6J 		abnormal dopaminergic neuron morphology J:167767
abnormal excitatory postsynaptic currents J:167767
decreased dopamine level J:167767
impaired behavioral response to cocaine J:167767
Smotm2Amc/Smotm2Amc
Slc6a3tm1(cre)Xz/Slc6a3+
involves: 129S1/Sv * 129X1/SvJ 		normal nervous system phenotype J:188348
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/23/2024
MGI 6.23 		The Jackson Laboratory